Cost-Effectiveness of Tepotinib Versus Capmatinib for the Treatment of Adult Patients With Metastatic Non–Small Cell Lung Cancer Harboring Mesenchymal–Epithelial Transition Exon 14 Skipping

From the US Medicare perspective, this study compared the cost-effectiveness of tepotinib and capmatinib for treating metastatic non–small cell lung cancer with tumors harboring mesenchymal–epithelial transition factor gene exon 14 skipping. A 3-state partitioned survival model assessed outcomes ove...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Value in health 2023-04, Vol.26 (4), p.487-497
Hauptverfasser:	Yang, Mo, Vioix, Helene, Sachdev, Rameet, Stargardter, Matthew, Tosh, Jon, Pfeiffer, Boris M., Paik, Paul K.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - genetics Cost-Benefit Analysis cost-effectiveness Exons Humans Lung Neoplasms - drug therapy Lung Neoplasms - genetics Medicare mesenchymal–epithelial transition factor gene exon 14 skipping metastatic non–small cell lung cancer Quality-Adjusted Life Years tepotinib tyrosine kinase inhibitors United States VISION trial
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!